These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 14585188)

  • 1. Cholestanol metabolism, molecular pathology, and nutritional implications.
    Seyama Y
    J Med Food; 2003; 6(3):217-24. PubMed ID: 14585188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterol 27-hydroxylase deficiency: a rare cause of xanthomas in normocholesterolemic humans.
    Björkhem I; Leitersdorf E
    Trends Endocrinol Metab; 2000 Jul; 11(5):180-3. PubMed ID: 10856919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
    Siman-Tov T; Meiner V; Gadoth N
    J Neurol Sci; 2006 Apr; 243(1-2):83-6. PubMed ID: 16445943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds.
    Moghadasian MH
    Clin Invest Med; 2004 Feb; 27(1):42-50. PubMed ID: 15061585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
    Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
    Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.
    Suh S; Kim HK; Park HD; Ki CS; Kim MY; Jin SM; Kim SW; Hur KY; Kim KW; Kim JH
    Eur J Med Genet; 2012 Jan; 55(1):71-4. PubMed ID: 21958693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
    Heller R; Grau AJ; Schäbitz WR; Schwaninger M
    Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presenile cataract: consider cholestanol.
    Tészás A; Pfund Z; Morava E; Kosztolányi G; Sistermans E; Wevers RA; Kellermayer R
    Arch Ophthalmol; 2006 Oct; 124(10):1490-2. PubMed ID: 17030721
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge.
    Björkhem I; Hansson M
    Biochem Biophys Res Commun; 2010 May; 396(1):46-9. PubMed ID: 20494109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
    Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrotendinous xanthomatosis.
    Björkhem I
    Curr Opin Lipidol; 2013 Aug; 24(4):283-7. PubMed ID: 23759795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.
    Appadurai V; DeBarber A; Chiang PW; Patel SB; Steiner RD; Tyler C; Bonnen PE
    Mol Genet Metab; 2015 Dec; 116(4):298-304. PubMed ID: 26643207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
    Keren Z; Falik-Zaccai TC
    Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects].
    Lionnet C; Carra C; Ayrignac X; Levade T; Gayraud D; Castelnovo G; Besson G; Androdias G; Vukusic S; Confavreux C; Zaenker C; De Seze J; Collongues N; Blanc F; Tranchant C; Wallon D; Hannequin D; Gerdelat-Mas A; Brassat D; Clanet M; Zephir H; Outteryck O; Vermersch P; Labauge P
    Rev Neurol (Paris); 2014; 170(6-7):445-53. PubMed ID: 24746394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrotendinous xanthomatosis (CTX)].
    Kinoshita M; Teramoto T
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):111-4. PubMed ID: 9645021
    [No Abstract]   [Full Text] [Related]  

  • 16. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
    Szalat A; Gershkovich P; Ben-Ari A; Shaish A; Liberman Y; Boutboul E; Gotkine M; Hoffman A; Harats D; Leitersdorf E; Meiner V
    Biochim Biophys Acta; 2007 Jul; 1771(7):839-44. PubMed ID: 17553741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathophysiology of cerebrotendinous xanthomatosis].
    Koyama S; Kato T
    Rinsho Shinkeigaku; 2016 Dec; 56(12):821-826. PubMed ID: 27840382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
    Weissfeld T; Ratliff J
    J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new mutations in sterol 27-hydroxylase gene in Japanese patients with cerebrotendinous xanthomatosis (CTX).
    Kim KS; Kubota S; Kuriyama M; Fujiyama J; Björkhem I; Eggertsen G; Seyama Y
    J Lipid Res; 1994 Jun; 35(6):1031-9. PubMed ID: 7915755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two novel mutations in the sterol 27-hydroxylase gene causing cerebrotendinous xanthomatosis.
    Lamon-Fava S; Schaefer EJ; Garuti R; Salen G; Calandra S
    Clin Genet; 2002 Mar; 61(3):185-91. PubMed ID: 12000359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.